- Home
- ARHS vs EWTX Comparison
ARHS vs EWTX Comparison
Compare ARHS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- EWTX
- Stock Information
- Founded
- ARHS 1986
- EWTX 2017
- Country
- ARHS United States
- EWTX United States
- Employees
- ARHS N/A
- EWTX N/A
- Industry
- ARHS Other Specialty Stores
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- EWTX Health Care
- Exchange
- ARHS Nasdaq
- EWTX Nasdaq
- Market Cap
- ARHS 1.2B
- EWTX 1.4B
- IPO Year
- ARHS 2021
- EWTX 2021
- Fundamental
- Price
- ARHS $8.23
- EWTX $13.36
- Analyst Decision
- ARHS Buy
- EWTX Buy
- Analyst Count
- ARHS 14
- EWTX 9
- Target Price
- ARHS $11.08
- EWTX $39.89
- AVG Volume (30 Days)
- ARHS 1.7M
- EWTX 759.8K
- Earning Date
- ARHS 08-07-2025
- EWTX 08-07-2025
- Dividend Yield
- ARHS N/A
- EWTX N/A
- EPS Growth
- ARHS N/A
- EWTX N/A
- EPS
- ARHS 0.41
- EWTX N/A
- Revenue
- ARHS $1,287,317,000.00
- EWTX N/A
- Revenue This Year
- ARHS $7.07
- EWTX N/A
- Revenue Next Year
- ARHS $7.64
- EWTX N/A
- P/E Ratio
- ARHS $20.00
- EWTX N/A
- Revenue Growth
- ARHS 0.71
- EWTX N/A
- 52 Week Low
- ARHS $6.61
- EWTX $10.60
- 52 Week High
- ARHS $17.27
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- ARHS 46.18
- EWTX 49.46
- Support Level
- ARHS $8.80
- EWTX $13.48
- Resistance Level
- ARHS $9.78
- EWTX $14.17
- Average True Range (ATR)
- ARHS 0.43
- EWTX 0.61
- MACD
- ARHS -0.03
- EWTX 0.11
- Stochastic Oscillator
- ARHS 20.08
- EWTX 67.86
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.